Here, we reviewed the recent literature regarding the clinical significance of the influenza virus infection ... hematopoietic stem-cell transplant (HSCT) recipients, and patients receiving ...

WHO declared the start of the COVID-19 pandemic. Although patients with haematological malignancies have greatly benefited ...

A timely medical intervention in the form of a bone marrow transplant, medically known as hematopoietic stem cell ...

Previous studies on regulatory T-cell (Treg) reconstitution after allogeneic hematopoietic SCT (HSCT) have suggested that, within the GVHD process, imbalance between effector T cells and Tregs may ...

Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone ...

FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy ...

Zydus Lifesciences announced that it has launch ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) ...

designed to protect patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) from infections, and other oral microbiome therapies in its pipeline. SER-155 is currently in the ...

The company launched ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will ...